Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.

ABSTRACT:

Purpose

Limited data exist regarding the activity of bendamustine in Hodgkin lymphoma (HL). This phase II study evaluated the efficacy of bendamustine in relapsed and refractory HL.

Patients and methods

Patients with relapsed and refractory HL who were ineligible for autologous stem-cell transplantation (ASCT), or for whom this treatment failed, received bendamustine 120 mg/m(2) as a 30-minute infusion on days 1 and 2 every 28 days with growth factor support. The primary end point was overall response rate (ORR). A secondary end point was referral rate to allogeneic stem-cell transplantation (alloSCT) for patients deemed eligible for alloSCT at the time of enrollment.

Results

Of the 36 patients enrolled, 34 were evaluable for response. Patients had received a median o

SUBMITTER: Moskowitz AJ 

PROVIDER: S-EPMC3862960 | biostudies-literature | 2013 Feb

REPOSITORIES: biostudies-literature